PROCEPT BioRobotics Co. (NASDAQ:PRCT) Shares Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board lifted its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 2,239.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 53,800 shares of the company's stock after purchasing an additional 51,500 shares during the quarter. Canada Pension Plan Investment Board owned about 0.10% of PROCEPT BioRobotics worth $4,332,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in PRCT. Wasatch Advisors LP purchased a new stake in PROCEPT BioRobotics during the fourth quarter worth about $3,413,000. EAM Global Investors LLC acquired a new stake in shares of PROCEPT BioRobotics during the 4th quarter valued at approximately $3,021,000. Jump Financial LLC boosted its stake in shares of PROCEPT BioRobotics by 318.0% during the 4th quarter. Jump Financial LLC now owns 49,865 shares of the company's stock worth $4,015,000 after acquiring an additional 37,935 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of PROCEPT BioRobotics in the 4th quarter worth approximately $389,000. Finally, Mariner LLC increased its stake in PROCEPT BioRobotics by 40.6% in the 4th quarter. Mariner LLC now owns 8,406 shares of the company's stock valued at $677,000 after purchasing an additional 2,429 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company's stock.

Insider Activity

In other news, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares in the company, valued at $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares in the company, valued at approximately $9,875,374.20. This trade represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock worth $368,322 over the last 90 days. Company insiders own 17.40% of the company's stock.

Analyst Ratings Changes

PRCT has been the topic of several research reports. Morgan Stanley lowered their target price on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a report on Wednesday, February 26th. Truist Financial dropped their price target on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, April 11th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $91.43.

PROCEPT BioRobotics Stock Down 1.2 %

Shares of PROCEPT BioRobotics stock opened at $52.80 on Wednesday. The company has a fifty day moving average price of $58.90 and a 200 day moving average price of $74.53. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. PROCEPT BioRobotics Co. has a twelve month low of $47.04 and a twelve month high of $103.81. The stock has a market cap of $2.89 billion, a price-to-earnings ratio of -27.08 and a beta of 1.09.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.01). The company had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. Equities research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).

Want to see what other hedge funds are holding PRCT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.